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One hundred and forty randomly selected liver trans-
plant recipients were studied before and after primary 
orthotopic liver transplantation for the presence or ab-
sence of CMV enteritis. Following OLTx, 65 patients 
were treated with cyclosporine A and 75 were treated 
with FK506. The two groups were similar with regard 
to the incidence, location, and outcome of their upper 
gastrointestinal CMV infection. Prior to OLTx, only one 
patient had evidence of enteric CMV infection. The in-
cidence of CMV enteritis post-OLTx was 27.7% in the 
CsA-treated group and 20% in the FK-treated group. 
During the first posttransplant month, no patient in the 
FK-treated group developed CMV enteritis, compared 
with 11.5% of the patients who were treated with CsA 
(P<0.05). Gastric CMV was found in over 80% of those 
positive for any organ in either group. In addition to 
CMV infection of the upper gastrointestinal tract, clin-
ically evident CMV disease involved more nonenteric 
organs in the CsA-treated group than in the FK-treated 
group. In the CsA-treated group, CMV -negative patients 
had a statistically higher I-year survival rate (100%) 
than CMV-positive patients (77.8%) (P<0.05). In the 
FK-treated group, no difference in survival was ob-
served between CMV-positive or CMV-negative cases at 
1 year. Of the patients on CsA, 20% received OKT3 for 
persistent rejection, as compared with 13% in the FK-
treated group. The patients receiving both CsA and 
OKT3 had a higher rate of upper gastrointestinal CMV 
infection than did FK-treated patients who also received 
OKT3 therapy (38.5% versus 20%, respectively). Based 
upon these data, it can be concluded that (1) patients 
receiving FK have a lower incidence of enteric CMV 
infection; (2) following OL Tx, upper gastrointestinal 
CMV infection presents later in FK-treated patients; (3) 
the stomach is the most frequently involved organ in the 
UGIT; (4) FK-treated liver recipients have less severe 
enteric CMV infection than do CsA-treated patients; (5) 
enteric CMV is not a major cause of mortality in liver 
transplant recipients; and (6) in patients receiving FK, 
those who require OKT3 therapy do not appear to be at 
a greater risk for the development of CMV enteritis than 
those who do not. 
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Gastrointestinal cytomegalovirus infection is a major clinical 
problem for organ transplant recipients because of its preva-
lence (1), morbidity, and potential lethality (2-4). Earlier stud-
ies from Pittsburgh have shown that upper gastrointestinal 
CMV infection is a frequent clinical problem in liver transplant 
recipients receiving cyclosporine A (5). FK506, a potent new 
immunosuppressive agent, is currently being used in recipients 
of liver transplants because of its greater potency (6, 7) and 
reduced frequency of untoward side effects (8). 
The purpose of this study was to compare the incidence, 
timing, location, and outcome associated with CMV infection 
of the upper gastrointestinal tract occurring in liver transplant 
recipients receiving either CsA or FK506. 
MATERIALS AND METHODS 
Patient population. The study population consisted of 140 patients 
who underwent primary orthotopic liver transplantation at the Uni-
versity of Pittsburgh between June 1987 and September 1990. Each 
subject was studied prospectively both before and after transplantation, 
based solely on the availability of one of the investigators at the time 
of his or her pre-OL Tx endoscopic procedure. The subjects were divided 
into two groups based on the primary immunosuppressive agent used 
in each case: group 1 consisted of patients who were given CsA (n=65), 
while group 2 consisted of patients receiving FK506 (n=75). Patients 
were followed until they were discharged from hospital, were switched 
to a new immunosuppressive agent (usually CsA to FK), or were 
retransplanted for graft failure regardless of the reason. The study 
population consisted of 70 males and 70 females. Their ages ranged 
from 16 to 67.5 years, with the mean being 44.3±2.5 years. 
Immunosuppressive therapy. Group 1 (CsA treatment): Patients in 
this group were given an intravenous induction dose for CsA (2 mg/ 
kg) and maintained on a dose of 2 mg/kg intravenously every 12 hr 
until oral therapy was possible, at which time the dose of CsA was 
changed to 8 mg/kg orally every 12 hr. All subsequent oral doses were 
regulated by monitoring daily serum CsA levels to maintain a thera-
peutic CsA level between 200 and 1000 ng/ml. Patients in this group 
were also given an initial intravenous dose of methylprednisolone (1 g/ 
day) and maintained at a dose of 20 mg/day intravenously until oral 
therapy was possible. At this time, a maintenance dose of 20 mg/day 
of oral prednisone was started. Azathioprine at a dose of 1-2 mg/kg 
orally was added to the immunosuppressive regimen of those patients 
who received one or more courses of OKT3 or required a reduction of 
CsA therapy because of nephrotoxicity. 
Group 2 (FK treatment): Patients in this group were given an 
intravenous induction dose of FK506 at 0.957 mg/kg. Subsequently, 
FK at a dose of 9.975 mg/kg was given twice a day intravenously until 
the patient was able to take the medicine orally at a dose of 0.15 mg/ 
kg/day in divided daily doses given every 12 hr. Therapeutic levels of 
FK506 were maintained between 0.5 and 2.0 mg/ml by adjusting the 
oral dose as necessary. Patients in this group did not receive methyl-
786 
r 
April 1992 SAKR ET AL. 787 
prednisolone intravenously but were given a maintenance oral dose of 
prednisone (20 mg/day) when oral therapy was possible. This dose was 
reduced on a regular basis as long as no evidence for liver rejection was 
evident. 
Supplemental immunotherapy. Biopsy-proven rejection episodes 
were treated either with one-gram methylprednisolone "pulses" given 
intravenously or with a "recycle" of oral prednisone in which the daily 
dose of prednisone was raised to 200 mg/day and tapered to a mainte-
nance level of 20 mg/day over the subsequent 5 days. Persistent 
rejection episodes were treated with a 5-day course of intravenous 
OKT3 at a dose of 10 mg/day. 
Endoscopic procedures. All patients underwent scheduled pre-OL Tx 
upper gastrointestinal endoscopy with biopsy of the second portion of 
the duodenum, gastric antrum, and lower esophagus using an Olympus 
GIF 2T10 endoscope and large biopsy forceps (Olympus FB 13K). 
Following OL Tx, any symptoms suggesting upper gastrointestinal dys-
function such as nausea, vomiting, gastric stasis, or bleeding was 
investigated by endoscopy. Many patients were endoscoped on multiple 
occasions, but always as indicated clinically. 
Histologic and virologic methods. Specimens were fixed in 10% for-
malin, dehydrated. embedded in paraffin, sectioned at five microns, 
and stained for histological examination with hematoxylin and eosin. 
All tissues suspicious for CMV infection based on the histology and/or 
viral culture results were examined further by using immunohistochem-
ical methods for the detection of CMV early and late antigens (9). 
Tissues for viral cultures were homogenized and cultured for CMV 
on human foreskin fibroblasts (Bartels Immunodiagnostic Supplies, 
Bellevue, WA) and A549 human lung carcinoma cell line (M.A. Bio-
products, Walersville, MD). Viral cultures were observed twice weekly 
for 3 weeks. Early antigen detection in cultures was achieved using 
MRC-5 cells seeded onto shell vials with centrifugation enhancement 
and staining with monoclonal antibody to CMV early nuclear antigen 
(Organon-Technica) at 18-24 hr after plating (10). 
Blood, urine, and throat cultures were not obtained on these patients 
unless clinically indicated. 
Diagnostic criteria. The diagnosis of CMV enteritis was based on the 
presence of either of the following criteria: (1) a positive culture of 
biopsied tissue, or (2) characteristic CMV inclusion bodies in stained 
tissues with immunohistochemical confirmation. 
Statistical analysis. All data are presented as the mean and the 
standard error of the mean. Chi-square analysis was used to evaluate 
associations as well as differences between proportions. Differences in 
the means were tested using the Student's test. A P value of <0.05 was 
considered to be significant. 
RESULTS 
The two groups were comparable in terms of age and gender, 
with almost an equal percentage of males and females in each 
group. There were no differences between the two groups in 
the type of liver disease necessitating transplantation (Table 
1). 
Incidence and timing of CMV infection. Pre-OLTx: Prior to 
transplantation, CMV infection in the upper gastrointestinal 
tract was documented in only one patient. Post-OL Tx, this 
patient was randomized to receive CsA (group 1) and was found 
to have clinically symptomatic CMV infection in the first 
posttransplant month. 
Post-OLTx: The incidence of CMV infection following OLTx 
was significantly greater than that occurring prior to 0 L Tx in 
both groups (P<O.OOl). The overall incidence of CMV infection 
among these liver recipients was 23.6% (33 of 140). A greater 
incidence of CMV infection was found in the CsA-treated group 
than in the FK-treated group (27.7% versus 20%, respectively), 
although this difference in incidence was not statistically sig-
nificant. The cumulative occurrence of upper gastrointestinal 
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TABLE 1. Demographic variables of study population 
Variables 
Age (years) 
Mean ± SE 
Range 
Sex 
Male 
Female 
Diagnostic category 
Parenchymatous 
Chronic active hepatitis 
Cryptogenic cirrhosis 
Drug-induced cirrhosis 
Alcoholic cirrhosis 
Hepatoma 
Metabolic liver disease 
Hemochromatosis 
Wilson's disease 
A-1-A deficiency 
Cholestatic disease 
Primary biliary cirrhosis 
Secondary biliary cirrhosis 
Sclerosing cholangitis 
Biliary atresia 
Other 
Fulminant hepatic failure 
Fulminant hepatitis A 
Fulminant hepatitis B 
Budd-Chiari syndrome 
Total (n = 140) 
esA group 
42.1±1.7 
18-67 
33 
32 
20 
9 
1 
11 
2 
o 
1 
o 
12 
o 
2 
3 
65 
100.------------------------------. 
80 
60 
40 
20 : ~ •• -.----------.---------
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o 234 5 6 
Months after transplantation 
F.K group 
47±1.6 
16-67.5 
37 
38 
22 
11 
2 
17 
4 
2 
o 
2 
5 
1 
7 
o 
1 
o 
o 
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FIGURE 1. Cumulative rate of upper gastrointestinal CMV infection 
post-OLTx in patients treated with CsA (group 1) or FK506 (group 2). 
CMV infection in both groups is shown graphically in Figure 
1. 
The mean time interval from the time of transplantation to 
the date of diagnosis of a CMV infection of the upper gastroin-
testinal tract was 6.1±0.6 weeks (range, 2 to 11 weeks) in the 
CsA-treated patients and 8.7±1 weeks (range, 5.1 to 21. 7 weeks) 
in the FK-treated patients (P<0.05). As may be seen in Table 
2 and Figure 2, no patient in the FK-treated group developed 
enteric CMV infection in the first postoperative month, com-
pared with 11.5% of patients who were endoscoped during this 
period in the CsA-treated group (P<0.05). Furthermore, in the 
----~--- ----------
788 TRA:-.iSPLANTATION Vol. 53, NO.4 
TABLE 2. Time of CMV infection in the CGIT post-OL Tx 
esA FK506 
Time post·OL Tx (months) 1'<0. patients o.1V+ No. patients CM\'+ 
endoscoped endoscoped 
26 3111.5%) 21 0(0%)' 
2 15 12 (80.0%) :26 9 (34.6<;;;)* 
3 4 3 (75.0%) 12 4 (33.3%)* 
>4 20 010%) 16 2 (12.5'C)* 
Total 65 18 (27.7%) 75 15 (20.0<;0) 
* Statistically significant differences in percentage of patients with 
documented upper gastrointestinal CMV infection. 
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FIGURE 2. Point frequency of upper gastrointestinal CMV infection 
post-OLTx in esA-treated patients (group 1) versus FK-treated pa-
tients (group 2) (* P<0.05) investigated at specific time points identified 
on the abscissa. 
CsA-treated group, 80% and 75% of the patients who under-
went endoscopy during the second and third months were found 
to have enteric CMV infection, as compared with 34.6% and 
33.3%, respectively, in the FK-treated group. These differences 
were statistically significant (P<0.05). In those recipients who 
developed CMV enteritis, no difference was found between the 
two groups with regard to the donor-recipient CMV serologic 
status. The liver donors were seropositive in 77.8% (14/18) of 
patients treated with CsA, as compared with 80% (12/15) in 
patients treated with FK. Prior to transplantation, 15 patients 
of the CsA-treated group (23.1 %) and 16 patients of the FK-
treated group (21.3%) did not have antibodies to CMV in their 
serum. In both groups, over 90C:-C of the seronegative recipients 
who received livers from seropositive donors developed CMV 
enteritis following transplantation. 
In CMV -positive patients, by the time of upper gastrointes-
tinal endoscopy, less than half of the FK-treated patients (7 
out of 15) were still on steroid maintenance therapy, with a 
mean dose of 13.7±3.2 mg/day (range 5-30 mg/day), whereas 
all patients in the CsA-treated patients were on steroid therapy, 
with a mean dose of 20.6±1 mg/day (range, 10-30 mg/day) 
(P<O.02). 
Enteric location of the CMV infection. Figure 3 shows the 
distribution of CMV infection in the upper gastrointestinal 
tract for both groups. In the two groups, the most common 
upper alimentary tract site found to be infected with CMV at 
any time was the stomach_ The stomach was involved in more 
than 80% of the cases demonstrating upper gastrointestinal 
tract involvement in any organ within this system. 
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FIGURE 3. Location of CMV in the UGIT on patients of CsA (group 
1) or FK506 (group 2) (E, esophagus; S, stomach; D, duodenum) . 
Morbidity of CMV infection. In both groups, patients expe-
rienced varying degrees of nausea, vomiting, and abdominal 
pain and discomfort with CMV enteritis. Another common 
presentation of CMV disease in both groups was fever E~PU°CF 
and chills with leucopenia (=::400/mm3 ) and a typicallympho-
cytosis (>3%). In the CsA-treated patients, the mean duration 
of fever was 14±3 days as compared with 10±1.2 days in the 
FK-treated patients. A positive blood buffy coat was detected 
in 14 CMV-positive patients (77.8%) treated with CsA as 
compared with 11 CMV-positive patients (73.3%) treated with 
FK. In addition to CMV infection in the upper gastrointestinal 
tract, the disease involved multiple organs including the liver 
(3 patients), lungs (2 patients), both liver and lungs (2 patients), 
and sigmoid colon (one patient) in the CsA-treated group, as 
compared with only one case of combined CMV hepatitis and 
pneumonitis and two cases of CMV retinitis in the FK-treated 
group. 
SurvivaL The overall I-year patient mortality rate in the 
total study population was 8.6% (12 of 140). Of the eight deaths 
in the FK-treated group, only one patient was CMV-positive 
and died of disseminated CMV infection. The four deaths in 
the CsA-treated group were all CMV-positive. Three of these 
four deaths were related to CMV infection. The I-year survival 
rates of CsA- and FK-treated patients are shown in Figures 4A 
and B. In the CsA-treated group, CMV -negative patients had 
a significantly higher I-year survival rate (100.0%) than CMV-
positive patients (77.8%) (P<0.05) (Fig. 4A). No significant 
difference in survival rates was observed between CMV -positive 
and CMV -negative cases (93.3% versus 86.3%, respectively) for 
the FK-treated group (Fig. 4B). The survival rates for CMV-
positive patients in the two immunosuppression groups, al-
though quite different, did not differ statistically_ Four more 
patients in the CsA-treated group died during the second post-
transplant year. Three of these patients were CMV -negative 
and one was CMV -positive. 
CMV infection and OKT3 antirejection therapy. Thirteen 
patients in the CsA-treated group received OKT3 (20%) for a 
persistent rejection episode as compared with 13% (10 patients) 
in the FK-treated group (NS). Five of the 13 patients in the 
CsA-treated group developed CMV infection (38.5%) as com-
pared with only two patients (20%) in the FK-treated group. 
This difference, however, was not statistically significant. No 
difference was found between patients who received OKT3 and 
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FIGURE 4. (A) Survival among CMV-positive and CMV·negative 
patients treated with CsA (* P<O.05). (8) Survival among CMV -positive 
and CMV·negative patients treated with FK506. 
those who did not receive OKT3 in either group in terms of the 
time or location of CMV infection in the upper gastrointestinal 
tract post-OL Tx. A potentially important finding is that CMV-
positive patients on OKT3 in the CsA·treated group had a 
mortality rate of 40% (two of five) as compared with 0% (0 of 
2) in the FK·treated group. Despite the apparently obvious 
difference between these two figures, this difference is not 
statistically significant, because the number of patients in each 
group who died was small. Moreover, it cannot be ascribed 
solely to the presence or absence of CMV infection, as a 
multivariate analysis assessing preoperative steroid and anti-
biotic use, blood product administration, the postoperative use 
of azathioprine, the postoperative steroid dose used, and the 
frequency of rejection episodes, as well as other variables, was 
not accomplished. Whenever identified, CMV infection was 
treated with gancyclovir in these patients. 
DISCUSSION 
In the present study, no association between the demographic 
variables of sex, age, or pretransplant liver diagnosis and the 
occurrence of CMV infection was evident in either group. 
Similar observations have been reported by others using CsA 
(11, 12) and FK506 (12) as the primary immunosuppressive 
agent. The two groups also were comparable with regard to the 
location of CMV infection in the upper gastrointestinal tract 
of those found to have CMV infection (Fig. 3). The stomach 
was the most frequently involved site in both groups. The 
esophagus was the least often involved organ. This finding also 
agrees with earlier reports (13, 14) and confirms the reduced 
incidence of CMV infection within squamous cell mucosal 
surfaces as compared with mucous· secreting mucosal surfaces 
(15, 16). 
Gastrointestinal involvement is a frequent manifestation of 
CMV infection in liver transplant recipients (4). Since the 
introduction of CsA into clinical organ transplantation, several 
studies have documented a lower incidence of symptomatic 
CMV infection in CsA·treated patients than that seen prior to 
the introduction of CsA (17, 18). 
With the introduction of FK506 into clinical liver transplan· 
tation at the University of Pittsburgh in February 1989 (19), 
the frequency of allograft rejection and the range of side effects 
experienced as a result of immunosuppression experienced in 
OLTx recipients have declined markedly (8). 
Prior to transplantation, CMV infection was documented in 
the upper gastrointestinal tract of only one patient (0.7%). 
Gastrointestinal CMV disease has been described rarely in 
normal individuals (13) and is also known to occur occasionally 
in patients with advanced liver disease (20). Because of its 
ability to reactivate in patients receiving immunosuppression, 
an increased incidence of CMV infection has been seen in 
transplant recipients as compared with those studied prior to 
OLTx (21,22). 
CMV disease is the most frequent infection experienced 
following liver transplantation (11,23). The upper gastrointes-
tinal tract is the most frequent site of clinically evident CMV 
infection in organ transplant recipients (24). The present study 
demonstrates that patients on FK506 following OL Tx have an 
overall lower rate of CMV infection than CsA-treated patients 
(20% versus 27.7%, respectively) (Fig. 1). This figure for the 
incidence of CMV infection in CsA·treated subjects is com· 
parable to that reported by several other groups (11,23, 25). 
The critical period for CMV enteritis following OLTx is the 
first 2-3 posttransplant months (4, 11). In the present series, 
during the first 3 post·OLTx months, CMV infection was 
significantly reduced in the FK-treated group as compared with 
the CsA·treated group (P<0.05) (Table 2 and Fig. 2). It is 
notable that no case of CMV enteritis was observed in the FK-
treated group during the first postoperative month. The occur-
rence of CMV enteritis during this critical period is presumably 
a consequence of the intense immunosuppression required dur-
ing this early period to prevent allograft rejection (26, 27). In 
the present study, FK·treated patients had a reduced rate of 
early graft rejection and as a result they received less "other 
agent" immunosuppressive therapy. Both immunosuppression 
and rejection episodes per se have been shown to enhance the 
rate of CMV infections (28). The present data demonstrate 
that no case of CMV enteric disease was detected by the end 
of the fifth posttransplant month in either group during the 
subsequent 12-26-month period of follow·up (Fig. 2). This 
finding is consistent with the earlier reports that over 90% of 
the infections occurring later than 6 months following trans· 
plantation are bacterial (11). On the other hand, our data show 
no difference between the two groups in terms of the relation· 
ship between the occurrence of CMV enteritis and the donor-
recipient serologic type. Further. our results show a high 
incidence (>90%) of primary enteric CMV infection in liver 
transplant recipients treated with either CsA or FK506. This 
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FIGURE 5. Survival curve of the FK· and CsA·treated groups. 
linding is consistent with similar serological evidence that 
hepatic (29) and other major organ transplantation (30-32) is 
associated with transmission of CMV. 
Based on the association of nausea, vomiting, and clinical 
evidence for gastric atony in patients with CMV enteritis, any 
transplant recipient manifesting these signs or symptoms prob-
ably ought to be endoscoped and biopsied to identify CMV 
disease before it becomes overtly evident or involves critical 
organs such as the liver or lungs. 
The outcome of transplantation can be influenced by CMV 
infection (11, 23,33, 34). In the present study, survival of CMV-
positive patients on CsA (group 1) was significantly lower 
(P<0.05), at 12 months post-OLTx, than that ofCMV-negative 
patients receiving CsA therapy (77.8% versus 100%, respec-
tively) (Fig. 4A). In the FK-treated group (group 2), no signif-
icant difference in survival at 12 months post-OL Tx between 
CMV'positive and CMV-negative patients could be demon-
strated (Fig. 4B). When the survival rates of CMV-positive 
patients in the two groups were compared, the survival rate of 
FK·treated patients was not statistically different from that of 
the CsA-treated group (Fig. 5). 
OKT3 antibodies provide a powerful means with which to 
treat steroid· resistant rejection episodes (35), Whereas some 
investigators have reported that patients who received OKT3 
therapy have a greater incidence of CMV infections (29, 36), 
others have failed to find such an effect (11, 25). In the present 
study, a higher frequency of upper gastrointestinal CMV infec-
tion was associated with a higher mortality in the patients who 
received OKT3 in the CsA-treated group but not in the FK-
treated group. Both groups were treated identically with gan-
cyclovir once CMV enteritis was identified. 
In summary, this study demonstrates that, following OL Tx, 
upper gastrointestinal CMV infection appears later in FK· 
treated patients than in CsA-treated patients. Patients on FK 
have a significantly lower rate of CMV infection in the first 3 
posttransplant months than do CsA-treated subjects. The 
stomach is the most frequently involved organ in the UGIT 
affected by CMV. In addition to CMV infection of the upper 
gastrointestinal tract, other organs were more involved in CsA-
treated patients than in FK-treated patients. Patients who 
receive OKT3 therapy while taking FK506 do not appear at a 
higher risk of developing CMV infection. This differs from 
what is seen in CsA-treated patients. Finally, although gas-
trointestinal CMV infection continues to be a major cause of 
morbidity in liver transplant recipients, it is no longer a major 
cause of mortality. It is likely that CMV infections will be 
reduced further as improved immunosuppressive protocols are 
developed utilizing lower doses of FK506 than those currently 
being used. 
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THE CORRELATION BETWEEN CYTOLOGICAL PATTERNS IN 
BILE AND HISTOLOGICAL FINDINGS IN LIVER 
TRANSPLANT ATION1 
KEIICHI KUBOTA,2.3 BO-GORAN ERICZON,2 AND FINN P. REINHOLT3•4 
Departments of Transplantation Surgery and Pathology, Karolinska Institute, Huddinge Hospital. Stockholm, Sweden 
The cytological patterns in bile were compared with 
the histological findings in concomitant specimens from 
liver transplants. In cases where cytology showed a 
moderate (n=10) or high cell density (n=8), histology 
demonstrated rejection in 14 of 18 specimens and chol-
angitis in 4. When the cell density was low (n=22), 
histology was nearly normal in 3 specimens and showed 
cholangitis in 9, while rejection was observed in 10 
specimens. Cell density in bile did not correlate Quan-
tatively with the severity of cellular infiltration in the 
portal triads or with the percentage of bile ducts at-
tacked by inflammatory cells. The results of the present 
study support our hypothesis that an increased concen-
1 Supported by Magnus Nasiell's Memorial Fund. 
2 Department of Transplantation Surgery. 
3 Department of Pathology. 
• Address correspondence and reprint requests to Finn P. Reinholt, 
M.D., Ph.D., Department of Pathology. Karolinska Institute. Huddinge 
Hospital F42. S-141 86 Huddinge. Sweden. 
tration of cells in bile is indicative of liver transplant 
rejection (sensitivity 58%), while normal cytology does 
not rule out the possibility of rejection (specificity 75%). 
During the early postoperative phase, bile from liver trans-
plants can be obtained at any time through a T tube or stent 
tube, and is therefore readily available for analysis. The color 
and volume of bile as well as the lipid composition (1) are 
clinically useful for evaluating liver transplant function. When 
it comes to the diagnosis of transplant rejection, although a 
change in the color and volume of the bile may raise clinical 
suspicion of rejection. the final diagnosis is usually based on 
the findings in a core needle biopsy or fine-needle aspiration 
biopsy (2, 3). However, because a core needle biopsy involves 
an invasive procedure, such material is usually not available 
for daily examination in the early postoperative phase (4). 
At our institution, we have taken advantage of the availabil-
ity of bile in these patients and. by applying the same meth-
odology as for pancreatic juice cytology in pancreatic trans-
